Ocular Therapeutix develops therapies for eye diseases using bioresorbable hydrogel technology. Products include DEXTENZA for post-surgical ocular inflammation and pain. AXPAXLI is being developed for wet age-related macular degeneration and retinal diseases. PAXTRAVA treats open-angle glaucoma or ocular hypertension. OTX-CSI treats dry eye disease, while OTX-DED is in phase 2 trials for dry eye symptoms. The company collaborates with Regeneron Pharmaceuticals on retinal disease treatments and AffaMed Therapeutics on DEXTENZA and OTX-TIC. Ocular Therapeutix was incorporated in 2006 and is headquartered in Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 2.1 |